Trial Profile
A study evaluating safety and efficacy of on-demand intramuscular recombinant human complement-C1-inhibitor-protein
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 23 Mar 2018
Price :
$35
*
At a glance
- Drugs Complement C1 inhibitor protein (Primary)
- Indications Hereditary angioedema
- Focus Adverse reactions; Therapeutic Use
- 23 Mar 2018 New trial record
- 05 Mar 2018 Results (n=5) assessing the intramuscular recombinant human complement-C1-inhibitor-protein as an alternatiev to intravenous treatment of hereditary angioedema, were presented at the 2018 Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
- 05 Mar 2018 Results presented at the 2018 Annual Meeting of the American Academy of Allergy, Asthma and Immunology